Skp2 Inhibitor C1
Based on 8 publication(s) in Google Scholar
Skp2 Inhibitor C1 (SKPin C1) is an S-phase kinase-related protein 2 (Skp2) inhibitor with an inhibitory effect on metastatic melanoma cells. Skp2 Inhibitor C1 slows the cell cycle, inhibits cell proliferation, and triggers apoptosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.05%
- CAS No.: 432001-69-9
- Formule: C18H13BrN2O4S2
- Masse moléculaire:465.34
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Covalent Screening Library
HY-L036
-
Oxygen Sensing Compound Library
HY-L045
-
Ubiquitination Compound Library
HY-L050
-
Anti-Liver Cancer Compound Library
HY-L101
-
Metabolic Enzyme Compound Library
HY-L146
-
Mitophagy Compound Library
HY-L180
-
Bioactive Compound Library Max
HY-L181
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
Amino Acid Metabolism Compound Library
HY-L189
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) Skp2 Inhibitor C1
More- Cancer Lett. 2024 Jun 1:591:216848. [Abstract]
- Leukemia. 2020 May;34(5):1241-1252. [Abstract]
- Int Immunopharmacol. 2023 Aug:121:110452. [Abstract]
- Mol Med Rep. 2016 Oct;14(4):3917-24. [Abstract]
- Transl Oncol. 2020 Oct;13(10):100809. [Abstract]
- Neoplasia. 2023 Apr:38:100890. [Abstract]
- Oncol Rep. 2016 Jul;36(1):559-66. [Abstract]
- Behav Pharmacol. 2021 Feb 1;32(1):62-72. [Abstract]
Customer Validation & Images
-
WB
-
WB
Activité biologique
Skp2 Inhibitor C1 (10-50 μM; 12 hr) decreases the viability of THP-1, U266 and RPMI 8226 cells[1].
Skp2 Inhibitor C1 (25 μM) increases p27 protein levels in U266 and RPMI 8226 cells by inhibiting ubiquitination[1].
Skp2 Inhibitor C1 (25 μM) inhibits cell cycle of U266 and RPMI 8226 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:B lymphocytes, THP-1, U266 and RPMI 8226 cells
-
Concentration:0, 5, 10, 25, and 50 μM
-
Incubation Time:12 hr, 24 hr, 36 hr, and 48 hr
-
Result:Significantly decreased the viability of U266 and RPMI 8226 cells at 10 μM for 12 hours.
Did not significantly affect B lymphocyte viability at 50 μM.
Decreased THP-1 cell viability at 50 μM for 12 hours.
-
Cell Line:U266 and RPMI 8226 cells
-
Concentration:0, 5, 10, 25, and 50 μM
-
Incubation Time:12 hr
-
Result:Increased the percentages of U266 and RPMI 8226 cells in the G0/G1 phase, while decreased the percentages in S and G2/M phases.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 432001-69-9
-
Appearance Solid
-
Masse moléculaire 465.34
-
Formule C18H13BrN2O4S2
-
Color White to yellow
-
SMILES
S=C(S/1)N(CC2=CN=CC=C2)C(C1=C\C(C=C(Br)C=C3)=C3OCC(O)=O)=O
-
Synonyms
SKPin C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Cancer Lett
2024 Jun 1:591:216848. PMID: 38604312 -
Leukemia
2020 May;34(5):1241-1252. PMID: 31772299 -
Int Immunopharmacol
Immunosensitivity mediated by downregulated AKT1-SKP2 induces anti-PD-1-associated thyroid immune injury. [Abstract]2023 Aug:121:110452. PMID: 37302368 -
Mol Med Rep
Inhibiting the role of Skp2 suppresses cell proliferation and tumorigenesis of human gastric cancer cells via the upregulation of p27kip1. [Abstract]2016 Oct;14(4):3917-24. PMID: 27572672
Skp2 Inhibitor C1 purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2016 Oct;14(4):3917-24. [Abstract]
BGC 823 human gastric cancer cells (3×105 cells/well) are plated into 48 well plates. After 6 h, the cells are treated with SKPin C1 at concentrations of 1, 5 and 10 μM for 48 h. The expression levels of Skp2 and p27kip1 are detected using western blot analysis and grey values are calcu-lated.
-
Transl Oncol
Skp2 depletion reduces tumor-initiating properties and promotes apoptosis in synovial sarcoma. [Abstract]2020 Oct;13(10):100809. PMID: 32623326 -
Neoplasia
Pharmacological inhibition of the SKP2/p300 signaling axis restricts castration-resistant prostate cancer. [Abstract]2023 Apr:38:100890. PMID: 36871351 -
Oncol Rep
2016 Jul;36(1):559-66. PMID: 27175797
Skp2 Inhibitor C1 purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2016 Jul;36(1):559-66. [Abstract]
Western blotting is performed to detect the expression of p21, p27 in PC-3-TxR cells and DU145-TxR cells treated with Paclitaxel or Skp2 inhibitors alone or their combination treatment. Paclitaxel or Skp2 inhibitor treatment alone leads to the accumulation of p27 in PC3-TxR or DU145-TxR.
-
Behav Pharmacol
Identification of the antidepressive properties of C1, a specific inhibitor of Skp2, in mice. [Abstract]2021 Feb 1;32(1):62-72. PMID: 33416256
Solvant et solubilité
DMSO : 20.83 mg/mL (44.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.47 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Yang Y, et al. Skp2 inhibitor SKPin C1 decreased viability and proliferation of multiple myeloma cells and induced apoptosis. Braz J Med Biol Res. 2019;52(5):e8412. [Content Brief]
[2]. Li F, et al. Identification of the antidepressive properties of C1, a specific inhibitor of Skp2, in mice. Behav Pharmacol. 2021 Feb 1;32(1):62-72. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1490 mL | 10.7448 mL | 21.4897 mL | 53.7242 mL |
| 5 mM | 0.4298 mL | 2.1490 mL | 4.2979 mL | 10.7448 mL | |
| 10 mM | 0.2149 mL | 1.0745 mL | 2.1490 mL | 5.3724 mL | |
| 15 mM | 0.1433 mL | 0.7163 mL | 1.4326 mL | 3.5816 mL | |
| 20 mM | 0.1074 mL | 0.5372 mL | 1.0745 mL | 2.6862 mL | |
| 25 mM | 0.0860 mL | 0.4298 mL | 0.8596 mL | 2.1490 mL | |
| 30 mM | 0.0716 mL | 0.3582 mL | 0.7163 mL | 1.7908 mL | |
| 40 mM | 0.0537 mL | 0.2686 mL | 0.5372 mL | 1.3431 mL |
Skp2 Inhibitor C1 Related Classifications
HY-16661 Related Classifications
Powered by Bioz